JP2020515589A5 - - Google Patents

Download PDF

Info

Publication number
JP2020515589A5
JP2020515589A5 JP2019553366A JP2019553366A JP2020515589A5 JP 2020515589 A5 JP2020515589 A5 JP 2020515589A5 JP 2019553366 A JP2019553366 A JP 2019553366A JP 2019553366 A JP2019553366 A JP 2019553366A JP 2020515589 A5 JP2020515589 A5 JP 2020515589A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019553366A
Other languages
English (en)
Japanese (ja)
Other versions
JP7196093B2 (ja
JP2020515589A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/026134 external-priority patent/WO2018187506A1/en
Publication of JP2020515589A publication Critical patent/JP2020515589A/ja
Publication of JP2020515589A5 publication Critical patent/JP2020515589A5/ja
Application granted granted Critical
Publication of JP7196093B2 publication Critical patent/JP7196093B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019553366A 2017-04-05 2018-04-04 Ask1阻害剤化合物とその使用 Active JP7196093B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762482085P 2017-04-05 2017-04-05
US62/482,085 2017-04-05
PCT/US2018/026134 WO2018187506A1 (en) 2017-04-05 2018-04-04 Ask1 inhibitor compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2020515589A JP2020515589A (ja) 2020-05-28
JP2020515589A5 true JP2020515589A5 (enExample) 2021-05-06
JP7196093B2 JP7196093B2 (ja) 2022-12-26

Family

ID=63712299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019553366A Active JP7196093B2 (ja) 2017-04-05 2018-04-04 Ask1阻害剤化合物とその使用

Country Status (34)

Country Link
US (3) US20210087167A1 (enExample)
EP (1) EP3606519B1 (enExample)
JP (1) JP7196093B2 (enExample)
KR (1) KR102665145B1 (enExample)
CN (1) CN110730661B (enExample)
AR (1) AR111407A1 (enExample)
AU (1) AU2018250217B2 (enExample)
CA (1) CA3059107A1 (enExample)
CL (1) CL2019002810A1 (enExample)
CO (1) CO2019011708A2 (enExample)
CR (1) CR20190503A (enExample)
CU (1) CU20190080A7 (enExample)
DK (1) DK3606519T3 (enExample)
DO (1) DOP2019000255A (enExample)
EA (1) EA201992299A1 (enExample)
EC (1) ECSP19078393A (enExample)
ES (1) ES2992084T3 (enExample)
FI (1) FI3606519T3 (enExample)
HU (1) HUE068103T2 (enExample)
IL (1) IL269711B (enExample)
JO (1) JOP20190221A1 (enExample)
MA (1) MA49047A (enExample)
MX (1) MX394098B (enExample)
NI (1) NI201900102A (enExample)
NZ (1) NZ758345A (enExample)
PE (1) PE20200009A1 (enExample)
PH (1) PH12019502288A1 (enExample)
PL (1) PL3606519T3 (enExample)
PT (1) PT3606519T (enExample)
RU (1) RU2019134679A (enExample)
SG (1) SG11201909155VA (enExample)
SI (1) SI3606519T1 (enExample)
TW (1) TWI779022B (enExample)
WO (1) WO2018187506A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787435B2 (en) * 2017-01-22 2020-09-29 Fuijan Cosunter Pharmaceutical Co. Ltd. ASK1 inhibitor and preparation method and use thereof
AU2018266911C1 (en) 2017-05-12 2022-10-20 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
EP3735404B1 (en) 2018-01-02 2023-11-29 Seal Rock Therapeutics, Inc. Ask1 inhibitor compounds and uses thereof
CN110407806B (zh) * 2018-04-28 2021-08-17 深圳微芯生物科技股份有限公司 甲酰胺类化合物、其制备方法及其应用
ES3004523T3 (en) 2018-05-02 2025-03-12 Enanta Pharm Inc Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10654833B2 (en) 2018-06-28 2020-05-19 Hepatikos Therapeutics, Llc ASK1 isoindolin-1-one inhibitors and methods of use thereof
WO2020041417A1 (en) 2018-08-22 2020-02-27 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020106707A1 (en) 2018-11-19 2020-05-28 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11466033B2 (en) 2019-03-25 2022-10-11 Enanta Pharmaceuticals, Inc. Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
CN112409332B (zh) * 2019-08-23 2023-12-08 广东东阳光药业股份有限公司 三氮唑衍生物及其在药物中的应用
PH12022551585A1 (en) 2019-12-27 2023-11-29 Lupin Ltd Substituted tricyclic compounds
CN115698004A (zh) 2020-05-01 2023-02-03 辉瑞公司 作为hpk1抑制剂的氮杂内酰胺化合物
WO2021224818A1 (en) * 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
WO2022029573A1 (en) * 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AR129959A1 (es) * 2022-07-20 2024-10-16 Seal Rock Therapeutics Inc Método para tratar enfermedades o trastornos orgánicos con inhibidores de ask1
WO2025233319A1 (en) 2024-05-06 2025-11-13 Genfit (1,2,4-triazol-3-yl)-2-pyridyl-1-isoindolinone for use in the treatment of sepsis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
TWI598347B (zh) * 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
PT2531501E (pt) * 2010-02-03 2014-02-17 Takeda Pharmaceutical Inibidores da cinase de regulação do sinal de apoptose 1
WO2012079022A1 (en) * 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EP2651417B1 (en) 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
JP2017528471A (ja) * 2014-09-24 2017-09-28 ギリアード サイエンシーズ, インコーポレイテッド 肝疾患を処置する方法
WO2017214359A1 (en) * 2016-06-10 2017-12-14 Venenum Biodesign Llc Novel clostridium difficile toxin inhibitors
US10787435B2 (en) 2017-01-22 2020-09-29 Fuijan Cosunter Pharmaceutical Co. Ltd. ASK1 inhibitor and preparation method and use thereof
EA037005B1 (ru) 2017-01-22 2021-01-26 Фуцзянь Косантер Фармасьютикал Ко., Лтд. Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
US11168095B2 (en) 2017-02-07 2021-11-09 Biogen Ma Inc. ASK1 inhibiting agents
WO2018149284A1 (zh) 2017-02-16 2018-08-23 四川科伦博泰生物医药股份有限公司 激酶抑制剂及其制备方法和用途
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
WO2018157277A1 (en) 2017-02-28 2018-09-07 Eli Lilly And Company Isoquinolin and naphthydrin compounds
KR20190126322A (ko) 2017-03-03 2019-11-11 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 아미드 유도체 억제제 및 그의 제조 방법 및 적용
JP2020512976A (ja) 2017-03-27 2020-04-30 ファーマケア,インク. アポトーシスシグナル調節キナーゼ1(ask1)阻害剤化合物
WO2019055540A1 (en) 2017-09-13 2019-03-21 D.E. Shaw Research, Llc COMPOUNDS AS INHIBITORS OF RAS AND THEIR USE
US10654833B2 (en) 2018-06-28 2020-05-19 Hepatikos Therapeutics, Llc ASK1 isoindolin-1-one inhibitors and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2020515589A5 (enExample)
JP2016516043A5 (enExample)
JP2020507589A5 (enExample)
JP2017523167A5 (enExample)
JP2016525136A5 (enExample)
JP2012506870A5 (enExample)
JP2019500387A5 (enExample)
JP2018527301A5 (ja) アジリジン含有dnaアルキル化剤
JP2015520769A5 (enExample)
TR201807321T4 (tr) Farnesoid x reseptörlerinin modüle edilmesi için bileşimler ve yöntemler.
JP2016534063A5 (enExample)
JP2017505785A5 (enExample)
JP2017523225A5 (enExample)
JP2012505234A5 (enExample)
JP2012505891A5 (enExample)
JP2020523330A5 (enExample)
JP2017526677A5 (enExample)
JP2012513416A5 (enExample)
JP2017531678A5 (enExample)
JP2016540811A5 (enExample)
WO2018075959A4 (en) Methods using hdac11 inhibitors
JP2019535723A5 (enExample)
JP2014528464A5 (enExample)
JP2010527985A5 (enExample)
JP2019527724A5 (enExample)